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Abstract
Pneumococcal pneumonia is a serious cause of morbidity and mortality in the elderly, but
investigation of the etiological agent of community-acquired pneumonia (CAP) is not possi-
ble in most hospitalized patients. The aim of this study was to estimate the effect of pneumo-
coccal polysaccharide vaccination (PPSV23) in preventing CAP hospitalization and
reducing the risk of intensive care unit admission (ICU) and fatal outcomes in hospitalized
people aged65 years. We made a multicenter case-control study in 20 Spanish hospitals
during 2013–2014 and 2014–2015. We selected patients aged65 years hospitalized with
a diagnosis of pneumonia and controls matched by sex, age and date of hospitalization.
Multivariate analysis was performed using conditional logistic regression to estimate vac-
cine effectiveness and unconditional logistic regression to evaluate the reduction in the risk
of severe and fatal outcomes. 1895 cases and 1895 controls were included; 13.7% of cases
and 14.4% of controls had received PPSV23 in the last five years. The effectiveness of
PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1–30.3). The benefit of
PPSV23 in avoiding ICU admission or death was 28.1% (95% CI -14.3–56.9) in all patients,
30.9% (95% CI -32.2–67.4) in immunocompetent patients and 26.9% (95% CI -38.6–64.8)
in immunocompromised patients. In conclusion, PPSV23 showed a modest trend to avoid-
ance of hospitalizations due to CAP and to the prevention of death or ICU admission in
elderly patients hospitalized with a diagnosis of CAP.
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Introduction
Streptococcus pneumoniae is a leading cause of serious illness, along with bacteremia, meningi-
tis and pneumonia. In adults aged65 years, most invasive cases result from the complica-
tions of pneumonia [1]. Pneumococcal disease causes a substantial burden among older adults
[2], and up to one third of patients require intensive care unit (ICU) admission and nearly
20% die during hospitalization or in the first month after discharge [3].
Recognition of continued morbidity and mortality due to pneumococcal infections despite
the use of appropriate antibiotics led to increased interest in disease prevention by vaccination
and, since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) containing anti-
gens against 23 of the 94 serotypes has been available [4]. Post-licensure studies showed the
vaccine is protective against invasive disease in immunocompetent older adults [5–7]. Evi-
dence in support of a beneficial effect of PPSV23 in preventing pneumococcal pneumonia is
more limited.
Until the 13-valent conjugate pneumococcal vaccination (PCV13) for adults recently
became available, PPSV23 vaccination was recommended in the United States for all persons
aged65 years and for adults aged<65 years at increased risk of invasive pneumococcal dis-
ease [8]. Similar recommendations are in place in most European Union countries, although
in France, the Netherlands, and Sweden vaccination is recommended only for adults with high
risk conditions and not for healthy adults aged65 years [9]. Currently, the recommended
pneumococcal vaccination schedule for adults aged65 years in the United States and other
countries is the administration of PCV13 followed by PPSV23 at least 1 year after PCV13 if the
subject has not received any previous pneumococcal vaccine and a dose of PCV13 if they have
previously received a PPSV23 dose (1 year after PPSV23) [10,11]. In adults aged65 years
with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid
leaks or cochlear implants, the recommended interval between PCV13 followed by PPSV23 is
8 weeks [12]. In contrast, in Spain as in other countries, the current recommendation is to
maintain PPSV23 vaccination in persons aged 65 years [13,14]. By the end of 2016, all Span-
ish regions included the PCV13 vaccine in the pediatric vaccination calendar; previously, only
two regions had included it.
Because samples for the investigation of the etiological agent are not always collected, path-
ogens are detected in only one third of all cases of community-acquired pneumonia (CAP)
[15] and, due to limitations in the sensitivity and specificity of the available diagnostic test, the
cause of pneumonia cannot be identified in most hospitalized patients [16]. Therefore, CAP is
an outcome of public health relevance that does not depend on the etiologic diagnosis, and
thus the study of PPSV23 vaccine effectiveness (VE) against hospitalized cases of CAP may be
considered a proxy of VE against pneumococcal pneumonia.
In Spain, CAP remains a major health problem in older adults [17] and free, universal
PPSV23 vaccination of people aged65 years has progressively been included in the vaccina-
tion schedule of some regions from 1999 onwards [18], although the coverage at any time
before data collection has remained < 50% [19]. According to the standing order strategy [20],
PPSV23 is administered in primary care centers or hospitals without requiring a specific order
from the attending physician [21].
Because S. pneumoniae infection in the elderly may result not only in CAP but also death
[22], it may be of interest to assess the benefit of pneumococcal vaccination in protecting
against the worst CAP outcomes, such as ICU admission and death.
The objective of this study was to estimate the effect of pneumococcal polysaccharide vacci-
nation in preventing CAP hospitalization in hospitalized subjects aged65 years and reducing
the risk of severe and fatal outcomes in CAP hospitalized subjects aged65 years.
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Methods
Study design
We carried out a multicenter case-control study in 20 hospitals from seven Spanish regions
(Andalusia, Castile and Leon, Catalonia, Madrid, Navarra, the Basque Country and Valencia
Community). Cases and corresponding controls admitted to participating hospitals between
September 2013 and June 2015 were recruited.
Selection of cases and controls
We selected patients aged65 years hospitalized for at least 24h with a diagnosis of CAP. The
diagnosis of pneumonia was based on the finding of a new infiltrate typical of pneumonia on
chest radiography, fever and any symptoms of lower respiratory tract infection. Pneumonia
was considered as nosocomial, and therefore excluded, if the onset of symptoms occurred
more than 48h after hospital admission [23].
One matched control was selected for each case from among patients with unplanned hos-
pital admission due to causes other than pneumonia or acute respiratory disease. Controls
were matched according to sex, age (±3 years) and date of hospitalization (preferentially ±10
days but ±30 days if no appropriate control was found using the ±10 day interval) and were
selected from patients admitted to the internal medicine service, general surgery, otorhinolar-
yngology, ophthalmology, dermatology, or traumatology services. When there was more than
one possible control for a case, the patient with a date of hospitalization ±10 days and with the
age closest to the case was chosen. Patients referred from nursing homes and those who did
not provide written informed consent were excluded.
Data collection
The following demographic variables and pre-existing medical conditions were recorded: age,
sex, marital status, educational level, smoking status, high alcohol consumption (>40gr/day
for men and>24gr/day for women), number of hospital visits during the last year, whether
the patient lived alone or with cohabitants, the Barthel index as a measurement of limitations
in activity (ranging from 0 -complete dependence- to 100 -complete independence), chronic
obstructive pulmonary disease (COPD), chronic respiratory failure, other lung diseases, neo-
plasia, transplantation, immunosuppressive treatment, asplenia, diabetes, renal failure,
nephrotic syndrome, autoimmune disease, AIDS, HIV infection, congestive heart disease, dis-
abling neurological disease, chronic liver disease, hemoglobinopathy or anemia, and cognitive
dysfunction. A severe outcome was defined as ICU admission or death. Information on influ-
enza vaccination in the current season and pneumococcal vaccination was collected by review
of the hospital medical record and, if this information was not contained in the hospital medi-
cal record, the primary care medical.
Given that antibody concentrations and effectiveness of the vaccine decline after 5–10 years
in elderly persons [24,25], the main analysis was made considering as vaccinated with the
pneumococcal vaccine cases and controls who had received a dose of PPVS2314 days and in
the 5 years before symptom onset (cases) or before symptom onset of the matched case (con-
trols). All other subjects were considered unvaccinated.
Cases were considered vaccinated with the current seasonal influenza vaccine if they had
received a dose of the vaccine14 days before symptom onset. Controls were considered vac-
cinated if they had received a dose of the vaccine at least 14 days before the onset of symptoms
of the matched case.
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Sample size calculation
The minimum sample size required, calculated using Schlesselman’s criteria [26], assuming a
PPSV23 rate among controls of 27.5%, a vaccination effectiveness of 24%, a statistical power of
80% and a confidence level of 95% according to previous studies [27], was 1118 cases and 1118
controls.
Statistical analysis
A bivariate comparison for matched data of demographic variables and medical conditions
between cases and controls was made using McNemar’s test. A two-tailed distribution was
assumed for all p-values.
To control for the possible influence of influenza viruses on CAP hospitalization, we con-
sidered two periods in each season: an epidemic period including the weeks when influenza
viruses circulated in Spain and a non-epidemic period including the remaining weeks. Accord-
ing to the reports of the Spanish network for epidemiological surveillance [28,29], epidemic
weeks were 25 November to 20 April in the 2013–2014 season and 24 November to 19 April in
the 2014–2015 season.
The interaction between PPSV23 and the other variables was analyzed.
Vaccine effectiveness (VE) was calculated using the formula: VE = (1 –OR) x 100.
A univariate conditional logistic regression model was used to estimate the crude VE in pre-
venting CAP hospitalization. Propensity score (PS) analysis was used to evaluate the adjusted
vaccine effectiveness. The PS was created using a logistic regression model with PPSV23 vacci-
nation status as the outcome and demographic variables, Barthel index, smoking and alcohol
intake, number of hospital visits, comorbidities, epidemic period and influenza vaccination as
independent variables. The PS was used as a covariate in the final conditional logistic regres-
sion model.
To assess the benefit of PPSV23 in avoiding severe outcomes in hospitalized patients we
compared the characteristics of hospitalized patients with CAP who died or were admitted to
the ICU with those of other hospitalized patients with CAP using unconditional logistic regres-
sion. We created a PS using a logistic regression model with PPSV23 vaccination status as the
outcome and demographic variables, Barthel index, smoking and alcohol intake, number of
hospital visits, comorbidities, epidemic period and influenza vaccination as independent vari-
ables. The PS was used as a covariate in the final unconditional logistic regression model.
The analysis was performed using the SPSS v.23 statistical package and the R v3.3.0 statisti-
cal software (http://cran.r-project.org).
Ethical considerations
All data collected were treated as confidential, in strict observance of legislation on observa-
tional studies. The study was approved by the Ethics Committees of the participating hospitals
(Comite´ E´tico de Investigacio´n Clı´nica del Hospital Clı´nic de Barcelona; Comite´ E´tico de
Investigacio´n Clı´nica del Hospital Universitari Mutua de Terrassa; Comite´ E´tico de Investiga-
cio´n Clı´nica de la Corporacio´ Sanitaria Parc Taulı´ de Sabadell; Comite´ E´tico de Investigacio´n
Clı´nica del Hospital de Mataro´, Consorci Sanitari del Maresme; Comite´ E`tic d’Investigacio´
Clı´nica de la Fundacio´ Unio Catalana Hospitals; Comite´ E´tico de Investigacio´n Clı´nica A´rea
de Euskadi; Comite´ E´tico de Investigacio´n Clı´nica A´rea de Salud de Burgos y Soria; Comite´
E´tico de Investigacio´n Clı´nica A´rea de Salud de Leo´n; Comite´ E´tico de Investigacio´n Clı´nica
A´rea de Salud Valladolid-Este; Comite´ Coordinador de E´tica de la Investigacio´n Biome´dica de
Andalucı´a; Comite´ E´tico de Investigacio´n Clı´nica del Hospital Ramo´n y Cajal, Madrid and
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Comite´ E´tico de Investigacio´n Clı´nica del Consorcio Hospital General Universitario de Valen-
cia). Written informed consent was obtained from all patients included in the study.
Results
A total of 1895 cases and 1895 controls were included in the study. The distribution of cases
and controls according to demographic variables, medical conditions and vaccination history
is shown in Table 1.
A total of 1003 cases (52.0%) and 923 controls (47.8%) had received pneumococcal vaccina-
tion and most (973 cases and 896 controls) had received PPSV23; only 5 cases and 5 controls
had received PCV13 alone and 16 cases and 8 controls had received both vaccines; 259 cases
and 272 controls had received PPSV23 in the previous 5 years. All patients who had received
PCV13 were excluded from the study of VE.
Of the 1895 cases with CAP, the etiological agent was determined in 469 (24.7%) and, of
these, S. pneumoniae was detected in 324 (69.1%).
Most patients hospitalized due to CAP (89.8%) and controls (86.5%) presented one or more
comorbidities, whose distribution is shown in Table 2.
Of the 1895 cases, 130 died within 30 days of admission and 81 were admitted to the ICU,
of whom 14 died.
No interaction between PPSV23 and comorbidities (p = 0.32) or age (p = 0.24) was
observed32).
The adjusted effectiveness of PPSV23 against CAP hospitalization is shown in Table 3 and
the benefit of PPSV23 in avoiding ICU admission or death in cases is shown in Table 4. The
effectiveness of PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1–30.3) in all
cases, which was not significant. The effectiveness of PPSV23 in preventing severe outcomes
in cases was 28.1% (95% CI -14.3–56.9) in all patients, 30.9% (95% CI -32.2–67.4) in immuno-
competent patients and 26.9% (95% CI -38.6–64.8) in immunocompromised patients.
S1 and S2 Tables show the VE excluding cases and controls vaccinated more than 5 years
previously. The VE against hospitalization was lower (6.1%; -21.8 to 27.6), but was significantly
higher (40.9%; 2.9–65.6; p = 0.04) in preventing ICU admission or death.
Discussion
The results of this study show that PPSV23 vaccination resulted in a non-significant trend to
protection against hospitalization due to CAP in the elderly and in preventing severe outcomes
when persons vaccinated5 years previously were considered unvaccinated, but offered sig-
nificant protection against severe outcomes when cases and controls vaccinated 5 years pre-
viously were excluded from the analysis (VE: 40.9%; 2.9–65.6).
Comparison of our results with other studies of CAP hospitalization in the elderly that con-
sidered patients vaccinated if they had received PPSV23 in the previous 5 years shows some
similarities. A case-control study in Japan in people aged65 years found no association
between vaccination in the previous 5 years and CAP [30]. In a Spanish cohort study in indi-
viduals aged60 years, vaccination within the last 5 years was not associated with a reduced
risk of all-cause CAP, but after exclusion of subjects who had received PPSV23 more than 5
years ago, vaccination was associated with a reduced risk for all-cause CAP hospitalization
(25%; 2–42) [31]. In a case-control study carried out in three Spanish regions five years after
the introduction of PPSV23, VE against CAP hospitalization was 23.6% (0.9–41) [27].
A meta-analysis of the last Cochrane review found a pooled estimate of vaccine efficacy of
28% (7–44) for all-cause pneumonia, but there was substantial variability in the effect estimate
Effectiveness of pneumococcal polysaccharide vaccination in the elderly
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due to heterogeneity, and the effectiveness of vaccination in preventing all-cause pneumonia
in adults could not be demonstrated [32]. In another meta-analysis, the pooled effect estimate
for preventing CAP was 7% (-19 to 28) among individuals who were vaccinated in the previous
five years [33].
Table 1. Distribution of cases and controls according to demographic variables, medical conditions and vaccination history.
Characteristics Cases (N = 1895) Controls (N = 1895) Crude OR (95% CI) p-value
Age group
65–74 years 592 (31.2%) 603 (31.8%) 1
75–84 years 879 (46.4%) 897 (47.3%) 1.17 (0.84–1.64) 0.36
85 years 424 (22.4%) 395 (20.8%) 1.69 (1.07–2.68) 0.03
Sex
Female 746 (39.4%) 746 (39.4%) -
Male 1149 (60.6%) 1149 (60.6%) -
Marital status
Married/Cohabiting 1099 (58.0%) 1108 (58.7%) 1
Single 140 (7.4%) 147 (7.8%) 0.96 (0.75–1.24) 0.77
Widowed 611 (32.3%) 607 (32.1%) 1.02 (0.87–1.20) 0.82
Separated/Divorced 44 (2.3%) 27 (1.4%) 1.66 (1.01–2.70) 0.04
Educational level
Without or primary 1378 (73.5%) 1308 (70.3%) 1
Secondary or higher 498 (26.5%) 553 (29.7%) 0.81 (0.69–0.95) 0.01
Household size
Live alone 339 (17.9%) 363 (19.2%) 1
Live with cohabitant 1555 (82.1%) 1526 (80.8%) 1.09 (0.93–1.29) 0.29
Barthel index
0–90 766 (40.4%) 773 (40.8%) 0.98 (0.85–1.13) 0.80
>90 1129 (59.6%) 1122 (59.2%) 1
Smoking status
Non smoker 838 (44.2%) 983 (51.9%) 1
Smoker 165 (8.7%) 145 (7.7%) 1.73 (1.31–2.27) <0.01
Ex-smoker 892 (47.1%) 767 (40.5%) 1.78 (1.48–2.14) <0.01
High alcohol consumption
Yes 71 (3.7%) 54 (2.8%) 1.34 (0.93–1.93) 0.12
No 1824 (96.3%) 1841 (97.2%) 1
No. of hospital visits
0–2 922 (48.9%) 897 (47.8%) 1
3 962 (51.1%) 978 (52.2%) 0.95 (0.82–1.10) 0.50
Risk medical conditions
No 193 (10.2%) 255 (13.5%) 1
Yes 1702 (89.8%) 1640 (86.5%) 1.38 (1.13–1.69) 0.002
Epidemiologic week
Yes 1302 (68.7%) 1266 (66.8%) 1.92 (1.31–2.83) 0.001
No 593 (31.3%) 629 (33.2%) 1
Influenza vaccine
Yes 891 (47.0%) 855 (45.1%) 1.10 (0.95–1.27) 0.19
No 1004 (53.0%) 1040 (54.9%) 1
Pneumococcal polysaccharide vaccine in 5 previous years
Yes 259 (13.7%) 272 (14.4%) 0.94 (0.78–1.14) 0.53
No 1636 (86.3%) 1623 (85.6%) 1
doi:10.1371/journal.pone.0171943.t001
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In a large case-control study in Connecticut, vaccination was effective against invasive
pneumococcal disease, but no VE was found in subjects aged65 years vaccinated more than
5 years ago [34]. A retrospective case-control study in Israel in subjects aged65 years found
that PPSV23 administered in the 5 previous years was effective against invasive pneumococcal
disease, but no protective effect against hospital-treated pneumonia was found (aOR: 1.01;
0.97–1.04) [35]. In Australia, using the screening method, VE against invasive pneumococcal
Table 2. Distribution of cases and controls according to comorbidities.
Characteristics Cases (N = 1895) Controls (N = 1895) Crude OR (95% CI) p-value
Immunocompetent
Chronic respiratory failure 381 (20.1%) 210 (11.1%) 2.22 (1.82–2.71) <0.001
Diabetes with complications 112 (5.9%) 134 (7.1%) 0.83 (0.64–1.07) 0.15
Diabetes without complications 534 (28.2%) 554 (29.2%) 0.95 (0.82–1.09) 0.47
Renal failure without hemodialysis 344 (18.2%) 369 (19.5%) 0.91 (0.77–1.08) 0.28
Autoimmune disease 89 (4.7%) 89 (4.7%) 1.00 (0.73–1.37) 1.00
Chronic obstructive pulmonary disease 570 (30.1%) 289 (15.3%) 2.60 (2.18–3.09) <0.001
Congestive heart disease 528 (27.9%) 563 (29.7%) 0.90 (0.77–1.05) 0.17
Neurological disease 155 (8.2%) 121 (6.4%) 1.30 (1.02–1.66) 0.04
Chronic liver disease 72 (3.8%) 106 (5.6%) 0.66 (0.48–0.90) 0.01
Cognitive dysfunction 229 (12.1%) 220 (11.6%) 1.05 (0.85–1.29) 0.63
Immunocompromised
Solid organ neoplasia 330 (17.4%) 398 (21.0%) 0.79 (0.67–0.93) 0.01
Hematologic neoplasia 47 (2.5%) 45 (2.4%) 1.04 (0.69–1.58) 0.83
Transplantation 20 (1.1%) 13 (0.7%) 1.54 (0.76–3.09) 0.23
Immunosuppressive treatment 73 (3.9%) 88 (4.6%) 0.82 (0.59–1.13) 0.22
Oral corticosteroid therapy 100 (5.3%) 61 (3.2%) 1.71 (1.22–2.38) 0.002
Asplenia 5 (0.3%) 4 (0.2%) 1.25 (0.34–4.65) 0.74
Renal failure with hemodialysis 31 (1.6%) 41 (2.2%) 0.75 (0.47–1.20) 0.23
Nephrotic syndrome 25 (1.3%) 9 (0.5%) 3.00 (1.35–6.68) 0.01
AIDS 3 (0.2%) 1 (0.1%) 3.00 (0.31–28.84) 0.34
HIV infection 3 (0.2%) 2 (0.1%) 1.50 (0.25–8.98) 0.66
Hemoglobinopathy or anemia 299 (15.8%) 328 (17.3%) 0.89 (0.74–1.06) 0.19
doi:10.1371/journal.pone.0171943.t002
Table 3. Crude and adjusted effectiveness of PPSV23 against hospitalization due to community-acquired pneumonia.
Cases vaccinateda/N
(%)
Controls vaccinateda/N
(%)
Crude vaccine effectiveness
(95% CI)
p-value Adjusted vaccine effectiveness
(95% CI)
p-value
All 259/1895 (13.7%) 272/1895 (14.4%) 5.8% (-13.7–21.9) 0.53 15.2% (-3.1–30.3) 0.10b
65–74
years
116/592 (19.6%) 133/592 (22.5%) 16.2% (-11.3–36.9) 0.22 23.6% (-3.0–43.3) 0.08c
75–84
years
94/879 (10.7%) 95/879 (10.8%) 1.2% (-34.5–27.5%) 0.94 11.5% (-22.1–35.9) 0.46d
85 years 49/424 (11.6%) 44/424 (10.4%) -12.8% (-73.6–26.7) 0.58 0.3% (-57.7–36.9) 0.99e
a In the 5 previous years. Adjusted for the propensity score.
Statistical power:
b 41%,
c46%,
d12%,
e3%
doi:10.1371/journal.pone.0171943.t003
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disease in subjects aged65 years in which those who received the vaccine in the previous 5
years was 71% (54–82) [36]. An indirect cohort study in Spain found that PPSV23 in the previ-
ous 5 years prevented 44% (24–60) of all invasive pneumococcal disease serotypes included in
the vaccine [37]. The estimate of these authors was clearly higher than ours, but this seems
logical because they investigated prevention against S. pneumoniae disease in which VE is
expected to be higher than against all CAP.
A possible explanation for the differences found in PPSV23 effectiveness against CAP hos-
pitalization might lie in the influence of the circulation of influenza viruses and other environ-
mental factors on bacterial complications [30,38–41]. To avoid the possible influence of these
factors, we defined the weeks when the influenza virus was circulating in Spain in each season
and introduced this variable in the estimate of PPSV23 effectiveness; however, this was not
done in the studies with negative results, making comparisons difficult.
No conclusions can be drawn on our estimates of VE in different age groups due to a lack
of statistical power, as also suggested in the study by Vila-Co´rcoles et al. [42].
In the present study, the effectiveness of PPSV23 in preventing ICU admission or death was
28.1% (95% CI -14.3–56.9) for all patients and 40.9% when subjects vaccinated more than 5
years previously were excluded (S2 Table). In a Spanish cohort study, vaccination within the
last 5 years was not associated with a reduced risk of death from CAP (1.04; 0.64–1.69) [31].
Other studies of subjects vaccinated at any time found that the protective effect of the PPSV23
against death was higher in immunocompetent than in immunocompromised patients
[5,43,44]. However, although effectiveness is attenuated in immunocompromised patients,
these are precisely the patients who have the most to gain by immunization as the risk of death
is higher [45].
In a recent randomized, placebo-controlled trial, the VE of the PCV13 against CAP in the
elderly was 45.6% (21.8–62.5) [46] and the benefit of the conjugate vaccine versus the polysac-
charide vaccine in avoiding deaths has also been reported [47]. Therefore, it may be questioned
whether the use of PCV13 would be more useful in preventing CAP in the elderly. The results
of several impact studies suggest that routine immunization with pneumococcal conjugate vac-
cines in children reduces the incidence of disease due to conjugate vaccine serotypes in the
elderly [48–51]. However, the epidemiology of specific serotypes evolves [52] and the duration
of immunity and the need for revaccination is not currently clear [53]. On the other hand, the
effect of herd immunity due to the direct effect of adult PCV13 vaccination remains unclear
[54]. In fact, the CDC states that routine PCV13 vaccination in adults aged65 years will be
reevaluated in 2018 [10].
Table 4. Effectiveness of the PPSV23 in avoiding intensive care unit admission or death in hospitalized patients with community-acquired
pneumonia.
Severe outcomes
vaccinateda/N (%)
Non severe outcomes
vaccinateda/N (%)
Crude vaccine
effectiveness (95% CI)
p-value Adjusted vaccine
effectiveness (95% CI)
p-value
All 21/211 (10.0%) 238/1684 (14.1%) 32.9% (-5.2–59.2) 0.09 28.1% (-14.3–56.9) 0.18b
Immunocompetent 10/97 (10.3%) 147/974 (15.1%) 35.3% (-21.6–69.1) 0.21 30.9% (-32.2–67.4) 0.30c
Immunocompromised 11/114 (9.6%) 91/710 (12.8%) 27.4% (-35.0–64.4) 0.34 26.9% (-38.6–64.8) 0.36d
a In the 5 previous years. Adjusted for the propensity score.
Statistical power:
b29%,
c20%,
d15%
doi:10.1371/journal.pone.0171943.t004
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A cost-effectiveness study carried out in the UK show that the incidence of vaccine-type
disease will probably be very low due to the wider benefits of childhood PCV13 vaccination
and that a specific PCV13 vaccination program targeting the immunocompetent elderly
would not be cost-effective [55]. A Dutch study found that PCV13 vaccination of immuno-
competent persons aged 65–74 years was not cost-effective, although vaccination of high-risk
individuals aged 65–74 years was cost-saving [56].
The results of the present and above-mentioned studies, together with the fact that PPSV23
includes eleven serotypes not found in PCV13, support the current indication for PPSV23 vac-
cination in the elderly and the interest in maintaining continuous surveillance of disease-caus-
ing serotypes in the elderly in order to evaluate the potential benefit and cost-effectiveness of
expanding PCV13 vaccination to all elderly persons.
One limitation of the present study is that the main analysis was carried out considering
persons not vaccinated in the previous five years as unvaccinated, which could have led to an
underestimate of the VE. Another possible limitation is that interviewers knew whether inter-
viewees were cases or controls, influencing information gathering. The same protocol was fol-
lowed in cases and controls and information on the vaccination history was collected from
information collected in medical records, vaccination cards or registers before the study
began. Therefore, it is unlikely that the results were affected by this possible information bias.
Most potential confounding factors described in the literature, including influenza vaccina-
tion and comorbidities, were taken into account and their possible effect limited by adjustment
[45]. Thus, although some residual confounding cannot be ruled out, this is unlikely to have
invalidated the results.
Cases were older and had more medical risk conditions than controls, and therefore were
more likely to receive the vaccine, but since a propensity score was used for the adjustment it
seems unlikely that this would invalidate the results.
Finally, because the number of Streptococcus pneumoniae cases found was very limited, it
was not possible to estimate VE in cases of S. pneumoniae CAP due to lack of statistical power.
In conclusion, the results of this study indicate that PPSV23 vaccination showed a modest
trend to avoidance of hospitalization due to CAP in elderly subjects and in preventing death or
ICU admission in elderly patients hospitalized with a diagnosis of CAP. The current indication
for PPSV23 vaccination in the elderly should be maintained but continuous surveillance of dis-
ease-causing serotypes in this population is required.
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